U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07531693) titled 'Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer' on April 09.
Brief Summary: The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Study Start Date: Feb. 19
Study Type: OBSERVATIONAL
Condition:
HR+/HER2- Early Breast Cancer
Recruitment Status: RECRUITING
Sponsor: Institut fuer Frauengesundheit
Disclaimer: Curated by HT Syndication....